Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

Executive Summary

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.

You may also be interested in...



First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA

Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.

Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay

European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel